HC Wainwright & Co. Maintains Buy on CytomX Therapeutics, Raises Price Target to $17

Benzinga Newsdesk www.benzinga.com Positive 72.2%

Neg 0% Neu 0% Pos 72.2%

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains CytomX Therapeutics (NASDAQ:CTMX) with a Buy and raises the price target from $10 to $17.